Our philosophy towards determining volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for Immune Pharmaceuticals which you can use to evaluate future volatility of the corporation. Please check out Immune Pharmaceuticals to validate if risk estimate we provide are consistent with the epected return of 0.0%.
|Horizon||30 Days Login to change|
Immune Pharmaceuticals Technical Analysis
We are not able to run technical analysis function on this symbol. We either do not have that equity or its historical data is not available at this time. Please try again later.
Immune Pharmaceuticals Projected Return Density Against MarketGiven the investment horizon of 30 days, Immune Pharmaceuticals has beta of 0.0 . This indicates the returns on DOW and Immune Pharmaceuticals do not appear to be highly reactive. Furthermore, It does not look like the company alpha can have any bearing on the equity current valuation.
Given the investment horizon of 30 days, the coefficient of variation of Immune Pharmaceuticals is 0.0. The daily returns are destributed with a variance of 0.0 and standard deviation of 0.0. The mean deviation of Immune Pharmaceuticals is currently at 0.0. For similar time horizon, the selected benchmark (DOW) has volatility of 0.88
|Alpha over DOW||=||0.00|
|Beta against DOW||=||0.00|
Immune Pharmaceuticals Return Volatilitythe corporate body inherits 0.0% risk (volatility on return distribution) over the 30 days horizon. the entity inherits 0.9129% risk (volatility on return distribution) over the 30 days horizon.
Immune Pharmaceuticals Investment Opportunity
DOW has a standard deviation of returns of 0.91 and is 9.223372036854776E16 times more volatile than Immune Pharmaceuticals. 0% of all equities and portfolios are less risky than Immune Pharmaceuticals. Compared to the overall equity markets, volatility of historical daily returns of Immune Pharmaceuticals is lower than 0 (%) of all global equities and portfolios over the last 30 days.
Immune Pharmaceuticals Current Risk Indicators
Immune Pharmaceuticals Suggested Diversification Pairs